Anavex net loss narrows to $5.3 million in Q2 FY26; R&D expenses drop to $4.2 million

Reuters2026/07/30 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Anavex posted a GAAP net loss of $5.3 million, or $0.06 per share, for fiscal Q2 ended March 31, 2026.
R&D expense fell to $4.19 million from $9.89 million a year earlier, due to completing the ANAVEX 3-71 schizophrenia trial.
G&A costs edged down to $2.29 million from $2.62 million in the year-ago quarter.
Cash and cash equivalents rose to $127.4 million as of March 31, 2026; the company expects funding into mid-to-late fiscal 2028.
Opened an FDA IND for early Alzheimer’s at end-March; DDI dosing is underway, ADME study initiation targeted for calendar Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300800PRIMZONEFULLFEED9800660) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anavex net loss narrows to $5.3 million in Q2 FY26; R&D expenses drop to $4.2 million

You may also like

Crypto prices